The European Medicines Agency denied an application by Thousand Oaks biotech giant Amgen and Brussels-based pharmaceutical firm UCB for the drug Evenity to treat patients with severe osteoporosis. The Committee for Medicinal Products for Human Use, or CHMP, said that it was concerned about trial results that showed an increased risk of heart attack or…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
